Loading stock data…
Cullinan Therapeutics, Inc. (CGEM)
$21.69-0.40 (-1.81%)
Market ClosedLast close Sep 8
Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Cullinan Therapeutics, Inc. in the Healthcare sector is trading at $21.69 with a market capitalization of $935M. Wall Street consensus targets $32.36 (11 analysts), implying a +49.2% move over the next 12 months. The stock is currently near its 52-week high of $23.19, remaining 47.7% above its 200-day moving average. On fundamentals, Piotroski 1/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 90/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +49.2% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$53.70M↑ | -$55.26M↑ | -$55.59M↑ | -$75.80M↓ | -$55.00M |
| Net Income | -$49.66M↑ | -$50.71M↓ | -$50.61M↑ | -$70.06M↓ | -$48.50M |
Peer Comparison
JNJUNHPFE
Fundamentals
Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. It engages in the development of CLN-978, a CD19xCD3 bispecific T cell engager for autoimmune disease...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$934.78M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
-0.09
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-60.36%
Volume
Today's trading volume
953,199
Recent News
New Taiho, Cullinan data heats up lung cancer drug battle
The findings position their drug, zipalertinib, as a threat to multiple approved medicines — while setting a bar for others in testing.
The Bull Case For Cullinan Therapeutics (CGEM) Could Change Following FDA-Backed Phase 2 CLN-049 Trial
Cullinan Therapeutics reported second-quarter 2026 results with a net loss of US$53.7 million and basic loss per share of US$0.81, both lower than a year earlier, alongside six-month net loss of US$103.37 million. The company also received positive U.S. FDA feedback that supports launching a potentially registrational Phase 2 trial for its FLT3xCD3 engager CLN-049 in relapsed/refractory acute myeloid leukemia, marking a key clinical and regulatory step for its lead program. We’ll now examine...
Cullinan Therapeutics (CGEM) Advances CLN 049 After FDA Feedback, Is The Upside Already Priced In?
Cullinan Therapeutics (CGEM) drew investor attention after receiving positive U.S. Food and Drug Administration feedback on its End of Phase 1 meeting for CLN-049 in acute myeloid leukemia. See our latest analysis for Cullinan Therapeutics. Against this backdrop, Cullinan Therapeutics’ share price has eased in the very short term, with a 1-day share price return of 1.49% lower and a 7-day return of 2.49% lower. However, the 90-day share price return of 31.88% and year to date share price...
VERAXA Biotech Stock in Focus as Lead Cancer Program Reaches Development Milestone
By Karen Roman VERAXA Biotech AG (Nasdaq: VRXA) said it started cell line development for its lead BiTAC T-cell engager program, collaborating with ATUM to apply proprietary technology for stable clonal cell line generation. “Today’s news underscores our commitment to accelerate the development path of our growing BiTAC-TCE portfolio,” said Christoph Erkel, Ph.D., VERAXA’s Vice […] The post VERAXA Biotech Stock in Focus as Lead Cancer Program Reaches Development Milestone appeared first on ExecE
Cullinan Therapeutics (CGEM) Is Up 27.1% After Autoimmune T Cell Engager Data Sparks Immune-Reset Hopes
Earlier in June 2026, Cullinan Therapeutics reported updated Phase 1 data showing CLN-978 and velinotamig produced strong clinical responses and favorable safety in treatment-refractory rheumatoid arthritis and systemic lupus erythematosus. The data, including clinical remission in a rituximab-refractory RA patient and complete renal responses in lupus nephritis, highlight Cullinan’s push to position T cell engagers as off-the-shelf immune-reset therapies across multiple autoimmune...